Home >> Tag Archives: Beckman Coulter Life Sciences—

Tag Archives: Beckman Coulter Life Sciences—

Beckman Coulter releases software for clinical labs

December 2018—Beckman Coulter launched Kaluza C Flow Cytometry Analysis Software, which aims to streamline clinical QC reporting and address standardization issues in flow cytometry. Kaluza C improves the visualization and analysis of rare events. It makes it possible to process large, multicolor files with up to 20 million events and set the plot resolution according to the gate level. The software enables the operator to focus on a limited number of events to preserve the integrity of the scatterplot.

Read More »

Beckman launches flow cytometry business tool

October 2018—Beckman Coulter launched its DURA Innovations Cost Benefit Calculator Tool, which allows flow cytometry customers to analyze areas of waste in the laboratory. The Cost Benefit Calculator helps the laboratory achieve greater efficiencies by identifying at least eight significant sources of waste.

Read More »

Antibody panels for rare event detection, 11/17

November 2017—Beckman Coulter Life Sciences has introduced DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).

Read More »

DuraClone RE antibody panels

Sept. 29, 2017—Beckman Coulter Life Sciences introduced its DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of either abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB). The three standardized, preformulated DuraClone RE kits, for research ...

Read More »

FDA-cleared IVD leukemia and lymphoma reagents

July 19, 2017—Beckman Coulter Life Sciences received FDA regulatory clearance, through the de novo process, to market its ClearLLab reagents for in vitro diagnostic use. The ClearLLab reagents deliver the first preformulated IVD antibody cocktails for leukemia and lymphoma immunophenotyping in the clinical laboratory. According to a June 29, 2017, news release from the FDA, the test “provides consistent results ...

Read More »
X